Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valiant LaboratoriesNSE:VALIANTLAB +2.27%51 Equity-to-Asset is 0.67 as of Mar. 2026, which is 6% above its 10-year median of 0.63. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹101.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Valiant Laboratories ranks better than 60.38% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Valiant Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2026 was ₹3,109 Mil. Valiant Laboratories's Total Assets for the quarter that ended in Mar. 2026 was ₹4,640 Mil.
Therefore, Valiant Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.67.
The historical rank and industry rank for Valiant Laboratories's Equity-to-Asset or its related term are showing as below:
NSE:VALIANTLAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.39 Med: 0.63 Max: 0.83
Current: 0.67
During the past 6 years, the highest Equity to Asset Ratio of Valiant Laboratories was 0.83. The lowest was 0.39. And the median was 0.63.
NSE:VALIANTLAB's Equity-to-Asset is ranked better than 60.38% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:VALIANTLAB: 0.67
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Valiant Laboratories Equity-to-Asset Related Terms
Valiant Laboratories Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Valiant Laboratories's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Equity-to-Asset of 0.67 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valiant Laboratories and its competitors. This is near median its historical median of 0.63. Over the past decade, Valiant Laboratories' Equity-to-Asset has ranged from 0.39 to 0.83. According to the industry distribution chart, Valiant Laboratories ranks #399 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 39.6%.
Is Valiant Laboratories' Equity-to-Asset too high?
Valiant Laboratories' current Equity-to-Asset of 0.67 is near median its 10-year median of 0.63. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 0.83. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Valiant Laboratories' value of 0.67 is 9.8% above this industry median. Based on the distribution chart, Valiant Laboratories ranks #399 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #399 out of 1007 companies for Equity-to-Asset. This puts Valiant Laboratories in the upper half of its industry. The industry median Equity-to-Asset is 0.61. Valiant Laboratories' value of 0.67 is 9.8% above this benchmark. Historically, Valiant Laboratories' own Equity-to-Asset has ranged from 0.39 to 0.83 over the past decade. While the company's 10-year median is 0.63 vs. the industry median of 0.61, Valiant Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Equity-to-Asset of 0.67 is 9.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Equity-to-Asset is 0.67, which is near median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹101.27, compared to a current price of ₹61.74 — trading 39% below its estimated fair value. The current Equity-to-Asset is 0.67, which is near median its 10-year median of 0.63 and 9.8% above the Drug Manufacturers industry median of 0.61. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Equity-to-Asset is 0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹61.74 is trading 39% below its estimated GF Value™ of ₹101.27.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Equity-to-Asset: 0.67 (near median its 10-year median of 0.63)
GF Value™: ₹101.27 vs. price of ₹61.74 (39% below fair value)
Industry Position: 9.8% above the Drug Manufacturers median (#399 of 1007)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
